Fig. 4From: Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in JapanOverall survival (OS) of patients treated with doublet therapy with anti-vascular endothelial growth factor (anti-VEGF) agents. Analysis of hazard ratio of OS based on RAS mutation status in patients with colorectal cancer using Cox regression analysis (N = 43). P-value: Log-rank analysisBack to article page